A learning opportunity provided by i3 Health has demonstrated significant knowledge gains and proficiency regarding the optimization of treating patients with relapsed/refractory (R/R) follicular lymphoma (FL). Non-Hodgkin lymphoma is one of the most prevalent cancers in the United States, with a 2022 estimate of around 80,470 people to be diagnosed, with 20,250 of these cases expected to be fatal. One in five of these cases will be FL, which is usually a slow-growing lymphoma but has the chance...

The FDA has announced that it has withdrawn its approval of umbralisib (Ukoniq®, TG Therapeutics) for treatment of marginal zone lymphoma (MZL) and follicular lymphoma (FL). Umbralisib had previously been granted accelerated approval in February 2021 based on the UNITY-NHL trial (NCT02793583). The withdrawal of this treatment was determined due to updated data from the UNITY-CLL trial (NCT02612311), which revealed a possible increased risk of death in patients receiving umbralisib. TG Therapeuti...

The FDA has given accelerated approval to tisagenlecleucel (Kymriah®, Novartis) for treatment of patients with relapsed or refractory (R/R) follicular lymphoma (FL) within six months of receiving two or more lines of systemic therapy or if the patient relapsed after an autologous hematopoietic stem cell transplant. "Follicular lymphoma is a common non-Hodgkin lymphoma that is generally considered indolent, but the disease remains incurable, and the majority of patients eventually relapse," wrote...

Follicular lymphoma is a disease that affects 2.7 per 100,000 individuals each year, with a five-year survival rate of 89.7%. It is the most common subtype of indolent non-Hodgkin's lymphoma; about 22% of newly diagnosed non-Hodgkin lymphoma cases are follicular lymphoma. The development of novel therapies offers new treatment options for patients living with follicular lymphoma. In this interview, Dr. Loretta J. Nastoupil, MD, Section Chief of New Drug Development in the Department of Lymphoma/...

Follicular lymphoma, an indolent, difficult-to-treat B-cell malignancy, is complicated by evolving disease subtypes. Patient outcomes can be hampered by the failure of the multidisciplinary team to establish consensus on the optimal timing, schedule, and length of follicular lymphoma treatment. In addition, the rapid pace of research makes it difficult to stay abreast of the latest and most clinically relevant therapies. This educational gap in the treatment and management of follicular lymphoma...

The FDA has granted accelerated approval to axicabtagene ciloleucel (Yescarta®, Kite Pharma, Inc.) for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy, including the combination of an anti-CD20 monoclonal antibody and an alkylating agent. An indolent form of non-Hodgkin lymphoma (NHL) that is not generally curable, FL is considered a chronic disease. Therefore, people living with FL often require second-line therapies after their di...

The latest data from the three-arm randomized phase 2 ECOG-ACRIN E2408 trial, which sought to improve upon frontline bendamustine/rituximab (BR) induction therapy followed by rituximab maintenance in untreated high-risk follicular lymphoma (FL), have yielded disappointing results: neither adding bortezomib to BR induction nor adding lenalidomide following BR induction improves outcomes. For the trial, 289 patients were randomized to receive either BR induction followed by two-year rituximab main...

Tazemetostat (TAZVERIK™, Epizyme, Inc.) has been approved for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) who have tumors that are positive for an EZH2 mutation, have received at least 2 previous systemic therapies, and have no satisfactory alternative treatment options. In addition, the FDA approved the cobas® EZH2 Mutation Test (Roche Molecular Systems, Inc.) as a companion diagnostic for tazemetostat. An EZH2 inhibitor, tazemetostat has previously been approved f...